Zymeworks BC Inc (NASDAQ:ZYME) price on Friday, February 28, rose 0.45% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $13.40.
A look at the stock’s price movement, the close in the last trading session was $13.34. Turning to its 52-week performance, $17.70 and $7.97 were the 52-week high and 52-week low respectively. Overall, ZYME moved -8.28% over the past month.
Zymeworks BC Inc’s market cap currently stands at around $930.61 million, with investors looking forward to this quarter’s earnings report slated for in April.
Analysts have a consensus estimate of 45.2M for the company’s revenue for the quarter, with a low and high estimate of 12.32M and 120M respectively. The average forecast suggests up to a 167.02% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 89.47M, representing a 17.71% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ZYME is a 50% Buy. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
4 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 3 recommend ZYME as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ZYME’s current price about -5.99% and -5.82% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 42.19, while 7-day volatility ratio is 5.32% and 5.07% in the 30-day chart. Further, Zymeworks BC Inc (ZYME) has a beta value of 1.13, and an average true range (ATR) of 0.71. Analysts have given the company’s stock an average 52-week price target of $19, forecast between a low of $12 and high of $28. Looking at the price targets, the low is 10.45% off current price level while to achieve the yearly target high, price needs to move -108.96%. Nonetheless, investors will most likely welcome a -41.79% jump to $19 which is the analysts’ median price.
If we refocus on Zymeworks BC Inc (NASDAQ:ZYME), historical trading data shows that trading volumes averaged 438.46K over the past 3 months. The company’s latest data on shares outstanding shows there are 69.58 million shares.
The 4.07% of Zymeworks BC Inc’s shares are in the hands of company insiders while institutional holders own 96.26% of the company’s shares. Current price change has pushed the stock -8.47% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ZYME stock continues to rise going into the next quarter.
